Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29635248 | 1.00 | KDM4E (0.49) | KDM4ELMNAPKMSMN1; SMN2GAA | |
| SCHEMBL3637105 | 0.91 | KDM4E (0.53) | KDM4ELMNAPKMSMN1; SMN2GAA | |
| SCHEMBL12575834 | 0.86 | LMNA (0.51) | KDM4ELMNAPKMSMN1; SMN2GAA | |
| SCHEMBL12490739 | 0.83 | KDM4E (0.47) | KDM4ELMNAPKMSMN1; SMN2GAA | |
| SCHEMBL31368630 | 0.81 | KMT2A (0.41) | KDM4ELMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL62649 | 0.81 | KMT2A (0.41) | KDM4ELMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL31368629 | 0.81 | KMT2A (0.41) | KDM4ELMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL24747246 | 0.80 | LMNA (0.44) | KDM4ELMNAPKMSMN1; SMN2GAA | |
| SCHEMBL14725188 | 0.80 | ALDH1A1 (0.46) | KDM4ELMNAPKMSMN1; SMN2GAA | |
| SCHEMBL24683837 | 0.80 | KDM4E (0.55) | KDM4ELMNAPKMSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025022299-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS IRAK-M DEGRADERS | GLENMARK PHARMACEUTICALS LTD (IN) | 2025-01-30 | — | — | WO | disclosed |
| EP-4327886-A2 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Libertas Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327886-A2 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | Libertas Bio, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3392252-B1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | LIBERTAS BIO INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3392252-B1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | LIBERTAS BIO INC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-108707151-B | Pyrimido-pyridazinone compounds and uses thereof | 阿萨纳生物科技有限责任公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ABS DEVELOPMENT 1, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ABS DEVELOPMENT 1, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10647720-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | Asan BioSciences, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647720-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | Asan BioSciences, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2013028818-A1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | ENDO PHARMACEUTICALS INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013028818-A1 | PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF | ENDO PHARMACEUTICALS INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-4556709-A | BACTERICIDES, FEED ADDITIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-03 | — | — | US | disclosed |
| US-3975384-A | ANTITHROMBOTICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190095-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | KDM4E 1625/4885LMNA 2970/4885PKM 427/4885 |
| US-10647720-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | THPO, TYMP, TYMS | KDM4E 1625/4885LMNA 2970/4885PKM 427/4885 |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | KDM4E 1625/4885LMNA 2970/4885PKM 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.